{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:09:54Z","timestamp":1779894594412,"version":"3.53.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T00:00:00Z","timestamp":1548806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1038\/s41409-019-0454-z","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T11:04:42Z","timestamp":1548846282000},"page":"1168-1172","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma"],"prefix":"10.1038","volume":"54","author":[{"given":"Khadega A.","family":"Abuelgasim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Alsharhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moataz","family":"Khairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Hommady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giamal","family":"Gmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hind","family":"Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6026-1347","authenticated-orcid":false,"given":"Bader","family":"Alahmari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad M.","family":"Masuadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0648-3256","authenticated-orcid":false,"given":"Ahmed","family":"Alaskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Alhejazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moussab","family":"Damlaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,30]]},"reference":[{"key":"454_CR1","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1038\/bmt.2015.6","volume":"50","author":"A Sureda","year":"2015","unstructured":"Sureda A, Bader P, Cesaro S, Dreger P, Duarte RF, Dufour C, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant. 2015;50:1037\u201356.","journal-title":"Bone Marrow Transplant"},{"key":"454_CR2","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.bbmt.2011.04.011","volume":"17","author":"JP Smeltzer","year":"2011","unstructured":"Smeltzer JP, Cashen AF, Zhang Q, Homb A, Dehdashti F, Abboud CN, et al. Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:1646\u201352.","journal-title":"Biol Blood Marrow Transplant"},{"key":"454_CR3","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/bmt.2017.143","volume":"52","author":"M Damlaj","year":"2017","unstructured":"Damlaj M, Ghazi S, Syed G, Pasha T, Gmati G, Salama H, et al. Pre-autologous transplantation PET\/CT using Deauville criteria is an independent predictor of progression in relapsed refractory classical Hodgkin lymphoma. Bone Marrow Transplant. 2017;52:1342\u20134.","journal-title":"Bone Marrow Transplant"},{"key":"454_CR4","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1182\/blood-2014-08-531582","volume":"126","author":"RSA Garcia-Sanz","year":"2015","unstructured":"Garcia-Sanz RSA, Alonso-Alvarez S, Gonzalez AP, Rodriguez A, Salar A, et al. Evaluation of the regimen brentuximab vedotin plus ESHAP (BRESHAP) in refractory or relapsed Hodgkin lymphoma patients: preliminary results of a phase I-II trial from the Spanish group of lymphoma and bone marrow transplantation (GELTAMO). Blood. 2015;126:582.","journal-title":"Blood"},{"key":"454_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","volume":"132","author":"AS LaCasce","year":"2018","unstructured":"LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132:40\u20138.","journal-title":"Blood"},{"key":"454_CR6","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","volume":"131","author":"AF Herrera","year":"2018","unstructured":"Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131:1183\u201394.","journal-title":"Blood"},{"key":"454_CR7","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"454_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3324\/haematol.10661","volume":"92","author":"A Santoro","year":"2007","unstructured":"Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin\u2019s lymphoma. Haematologica. 2007;92:35\u201341.","journal-title":"Haematologica"},{"key":"454_CR9","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","volume":"32","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048\u201358.","journal-title":"J Clin Oncol"},{"key":"454_CR10","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.bbmt.2006.06.006","volume":"12","author":"NS Majhail","year":"2006","unstructured":"Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin\u2019s lymphoma. Biol Blood Marrow Transplant. 2006;12:1065\u201372.","journal-title":"Biol Blood Marrow Transplant"},{"key":"454_CR11","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3324\/haematol.2011.047670","volume":"97","author":"D Villa","year":"2012","unstructured":"Villa D, Seshadri T, Puig N, Massey C, Tsang R, Keating A, et al. Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin\u2019s lymphoma resistant to platinum-containing first-line salvage chemotherapy. Haematologica. 2012;97:751\u20137.","journal-title":"Haematologica"},{"key":"454_CR12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(17)30912-9","volume":"19","author":"OA O\u2019Connor","year":"2018","unstructured":"O\u2019Connor OA, Lue JK, Sawas A, Amengual JE, Deng C, Kalac M, et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin\u2019s lymphoma: an international, multicentre, single-arm, phase 1-2 trial. Lancet Oncol. 2018;19:257\u201366.","journal-title":"Lancet Oncol"},{"key":"454_CR13","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","volume":"385","author":"CH Moskowitz","year":"2015","unstructured":"Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385:1853\u201362.","journal-title":"Lancet"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0454-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0454-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0454-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:14:00Z","timestamp":1684617240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-019-0454-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,30]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["454"],"URL":"https:\/\/doi.org\/10.1038\/s41409-019-0454-z","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,30]]},"assertion":[{"value":"13 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}